Advertisement

The Gastrointestinal Transit and Systemic Absorption of Diltiazem HCL from a Modified Release Dosage Form

  • Donald L. Heald
  • John A. Ziemniak
  • Ian R. Wilding

Abstract

The primary means of administration for the vast majority of therapeutic agents is via the oral route. Many of these oral dosage forms are designed to provide a rapid disintegration in the stomach, however, over the last 5–6 years there has been a growing trend within the pharmaceutical industry to develop complex pharmaceutical dosage forms designed to deliver drug in a controlled or timed released manner after oral administration. The design of these modified release (MR) drug products is intended to optimize the therapeutic regimen by providing slow continuous delivery of drug over the entire dosing interval while also providing greater patient compliance and convenience. The development of these MR dosage forms has also placed demands on the pharmaceutical industry to design and utilize new methodologies to assess the performance of these products in vivo. Likewise, regulatory agencies are faced with the arduous task of reviewing the performance of these new drug products to assure that the dosage forms perform as expected. The task of demonstrating the performance of the dosage form is the responsibility of the sponsoring pharmaceutical company.

Keywords

Dosage Form Tiaprofenic Acid Gastrointestinal Transit Gamma Scintigraphy Small Intestinal Transit Time 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Buckley M, Grant S, Goa K, McTavish D and Sorkin E (1990): Diltiazem: A reappraisal of its pharmacological properties and therapeutic use. Drugs 39: 757–806.CrossRefGoogle Scholar
  2. Channer K and Virjee J (1986): The effect of size and shape of the tablets on their oesophageal transit. J Clin Pharmacol 26: 141–146.Google Scholar
  3. Daly PB, Davis SS, Frier M, Hardy, JG, Kennerley JW and Wilson CG (1982): Scintigraphic assessment of the in vivo dissolution rat of a sustained release tablet. Int J Pharmacol 10: 17–24.CrossRefGoogle Scholar
  4. Davis S, Hardy J, Taylor M, Whalley D and Wilson C (1984): A comparative study of the gastrointestinal transit of a pellet and a tablet formulation. Int J Pharm 21: 167–177.CrossRefGoogle Scholar
  5. Davis S, Hardy J and Fara J (1986): Transit of pharmaceutical dosage forms through the small intestine. Gut 27: 886–892.CrossRefGoogle Scholar
  6. Davis SS (1987): The design and evaluation of controlled release dosage forms for oral drug delivery. STP Pharmac 3:412–417.Google Scholar
  7. Digenis G, Parr A and Jay M (1989): Neutron activation methods for evaluation of pharmaceutical dosage forms. In: Drug Delivery to the Gastrointestinal Tract, Hardy J, Davis S and Wilson C, eds. Chichester: Ellis Horwood.Google Scholar
  8. Digenis G and Sandefer E (1991): Gamma scintigraphy and neutron activation techniques in the in vivo assessment of orally administered dosage forms. Crit Rev Therap Drug Carrier Systems 7: 309–345.Google Scholar
  9. Digenis G, Sandefer E, Parr A, Beihn R, McClain C, Scheinthal B, Ghebre-Sellassie I, Iyer U, Nesbitt R and Randinitis E (1990): Gastrointestinal behavior of orally administered radiolabeled erythromycin pellets in man as determined by gamma scintigraphy. J Clin Pharmacol 30: 621–631.Google Scholar
  10. Fell J and Digenis G (1984): The in vivo behavior of solid oral dosage forms. Int J Pharm 22: 1.CrossRefGoogle Scholar
  11. Hardy J (1989): Radionuclide imaging in drug formulation, In: Radiopharmaceuticals Using Radioactive Compounds in Pharmaceutics and Medicine, Theobald A, ed. Chichester: Ellis Horwood.Google Scholar
  12. Hardy J, Lamont G, Evans D, Haga A and Gamst O (1991): Evaluation of an enteric-coated naproxen pellet formulation. Aliment Pharmacol Therap 5: 69–75.CrossRefGoogle Scholar
  13. Heald D, Ziemniak J and Wilding I. (1992): manuscript in preparation. Hey H, Jorgensen F, Sorensen K, Hasslebach H and Wamberg T (1982): Oesophageal transit of six commonly used tablets and capsules. Br Med J 285: 1717–1719.Google Scholar
  14. Khosla R, Feely LC and Davis S (1989): Gastro-intestinal transit of non-disintegrating tablets in the fed state. Int J Pharm 53: 107–117.CrossRefGoogle Scholar
  15. Jay M, Beihn R, Digenis G, DeLand F Caldwell L and Mlodozeniec A (1985): Disposition of radiolabeled suppositories in humans. J Pharm Pharmacol 37: 266.CrossRefGoogle Scholar
  16. Parr A, Jay M, Digenis G and Beihn R (1985): Radiolabelling of intact tablets by neutron activation for in vivo scintigraphic studies. J Pharm Sci 74: 590–591.CrossRefGoogle Scholar
  17. Parr A, Beihn R and Jay M (1986): In vivo scintigraphy evaluation of enteric coated tablets using neutron activation of erbium-170. Int J Pharm 32:251–256.CrossRefGoogle Scholar
  18. Parr A, Beihn R, Szpunar G and Jay M (1987): Correlation of ibuprofen bioavailability with gastrointestinal transit by scintigraphic monitoring. Pharm Res 4: 486–489.CrossRefGoogle Scholar
  19. Phillips S (1988): Small bowel. In: An Illustrated Guide to Gastrointestinal Motility, Kumar D and Gustavsson S, eds. Chichester: John Wiley and Sons.Google Scholar
  20. Richter H (1988): Stomach and duodenum. In: An illustrated Guide to Gastrointestinal Motility, Kumar D and Gustavssoer S, eds. Chichester: John Wiley and Sons.Google Scholar
  21. Vantrappe G, Janssens J, Hellemans J and Ghoos Y (1977): The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. Pharm Res 4: 486–489.Google Scholar
  22. Weiner D (1988): Calcium Channel Blockers. Med Clin North Am 72: 83–113.Google Scholar
  23. Wilding I, Coupe A and Davis S (1991): The role of γ-scintigraphy in oral drug delivery, Adv Drug Delivery Rev 7: 87–117.CrossRefGoogle Scholar
  24. Wilding I, Davis S, Sparrow R, Bloor J, Hayes G and Ward G (1992): The effect of food on the in vivo behavior of a novel sustained release formulation of tiaprofenic acid. Int J Pharm: in press.Google Scholar
  25. Wilson C, Washington N, Norman S, Greaves J, Peach J and Pugh K (1988): A gamma scintigraphic study to compare oesophageal clearance of ‘Expidet’ formulations, tablets and capsules in supine volunteers. Int J Pharm 46: 241–246.CrossRefGoogle Scholar
  26. Wilson C and Hardy J (1982): Radionuclide Imaging in Drug Research, London: Croom Helm.Google Scholar

Copyright information

© Birkhäuser Boston 1993

Authors and Affiliations

  • Donald L. Heald
    • 1
  • John A. Ziemniak
    • 1
  • Ian R. Wilding
    • 2
  1. 1.Drug Disposition DepartmentRhône-Poulenc RorerFrance
  2. 2.Pharmaceutical Profiles, LtdUK

Personalised recommendations